Literature DB >> 32507488

Coats-like Exudative Vitreoretinopathy in Retinitis Pigmentosa: Ocular Manifestations and Treatment Outcomes.

Omar Moinuddin1, Sanjana Sathrasala1, K Thiran Jayasundera1, Kari H Branham1, Emmanuel Y Chang2, Cynthia X Qian3, Franco M Recchia4, Abigail T Fahim1, Cagri G Besirli5.   

Abstract

PURPOSE: To provide a comprehensive review of the ocular manifestations, outcomes, and genetic findings in patients with Coats-like retinitis pigmentosa (RP).
DESIGN: Multicenter, retrospective, nonconsecutive case series. PARTICIPANTS: Patients with a diagnosis of RP demonstrating Coats-like exudative vitreoretinopathy between January 1, 2008, and October 1, 2019.
METHODS: Evaluation of ocular findings at RP diagnosis and at time of presentation of Coats-like exudative vitreoretinopathy, pedigree analysis, genetic testing, retinal imaging, and anatomic outcomes after treatment. MAIN OUTCOME MEASURES: Visual acuity, ophthalmoscopy results, OCT results, fluorescein angiography results, and identification of genetic mutations.
RESULTS: Nine patients diagnosed with RP and demonstrating Coats-like exudative vitreoretinopathy were included. Median age at time of RP diagnosis was 8 years (range, 1-22 years), and median age at presentation of Coats-like exudative vitreoretinopathy was 18 years (range, 1-41 years). Seven patients were female, and 2 were male. The genetic cause of disease was identified in 6 patients. Three patients demonstrated Coats-like fundus findings at the time of RP diagnosis. Exudative retinal detachment (ERD) localized to the infratemporal periphery was present in all patients, with bilateral disease observed in 7 patients. In all treated patients, focal laser photocoagulation was used to treat leaking telangiectasias and to limit further ERD expansion. Cystoid macular edema refractory to carbonic anhydrase inhibitor therapy and ultimately amenable to treatment with intravitreal anti-vascular endothelial growth factor injection was observed in 4 patients.
CONCLUSIONS: Coats-like vitreoretinopathy is present in up to 5% of all RP patients. The term Coats-like RP is used colloquially to describe this disease state, which can present at the time of RP diagnosis or, more commonly, develops late during the clinical course of patients with longstanding RP. Coats-like RP is distinct from Coats disease in that exudative pathologic features occur exclusively in the setting of a coexisting RP diagnosis, is restricted to the infratemporal retina, can affect both eyes, and does not demonstrate a male gender bias. Given the risk of added vision loss posed by exudative vitreoretinopathy in patients with RP, a heightened awareness of this condition is critical in facilitating timely intervention.
Copyright © 2020 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2020        PMID: 32507488      PMCID: PMC8086515          DOI: 10.1016/j.oret.2020.03.026

Source DB:  PubMed          Journal:  Ophthalmol Retina        ISSN: 2468-6530


  58 in total

1.  Cystoid macular oedema successfully treated by cryotherapy in retinitis pigmentosa with Coats'-like retinal exudation.

Authors:  G De Salvo; M Gemenetzi; A J Luff; A J Lotery
Journal:  Eye (Lond)       Date:  2011-02-25       Impact factor: 3.775

2.  X-linked retinitis pigmentosa. Profile of clinical findings.

Authors:  G A Fishman; M D Farber; D J Derlacki
Journal:  Arch Ophthalmol       Date:  1988-03

3.  Ranibizumab for neovascular age-related macular degeneration.

Authors:  Philip J Rosenfeld; David M Brown; Jeffrey S Heier; David S Boyer; Peter K Kaiser; Carol Y Chung; Robert Y Kim
Journal:  N Engl J Med       Date:  2006-10-05       Impact factor: 91.245

4.  A novel RPGR exon ORF15 mutation in a family with X-linked retinitis pigmentosa and Coats'-like exudative vasculopathy.

Authors:  F Yesim K Demirci; Brian W Rigatti; Tammy S Mah; Michael B Gorin
Journal:  Am J Ophthalmol       Date:  2006-01       Impact factor: 5.258

5.  Apoptotic photoreceptor cell death in mouse models of retinitis pigmentosa.

Authors:  C Portera-Cailliau; C H Sung; J Nathans; R Adler
Journal:  Proc Natl Acad Sci U S A       Date:  1994-02-01       Impact factor: 11.205

6.  Retinitis pigmentosa and exudative vasculopathy.

Authors:  J A Fogle; R B Welch; W R Green
Journal:  Arch Ophthalmol       Date:  1978-04

7.  [Coat's type retinitis pigmentosa].

Authors:  C H Ide; J A Khan; T L Podolsky; M P Strickland; R J Wilson
Journal:  Klin Monbl Augenheilkd       Date:  1987-03       Impact factor: 0.700

8.  Coats' disease: a study of 62 histologically confirmed cases.

Authors:  M M Chang; I W McLean; J C Merritt
Journal:  J Pediatr Ophthalmol Strabismus       Date:  1984 Sep-Oct       Impact factor: 1.402

9.  Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab.

Authors:  Nicholas Papadopoulos; Joel Martin; Qin Ruan; Ashique Rafique; Michael P Rosconi; Ergang Shi; Erica A Pyles; George D Yancopoulos; Neil Stahl; Stanley J Wiegand
Journal:  Angiogenesis       Date:  2012-06       Impact factor: 9.596

10.  Retinitis Pigmentosa Associated with Vasoproliferative Tumors and Coats-like Fundus.

Authors:  Fariba Ghassemi; Marjan Akbari-Kamrani
Journal:  J Ophthalmic Vis Res       Date:  2013-07
View more
  3 in total

1.  Case Report: A Case of Cystoid Macular Edema in Retinitis Pigmentosa With Central Retinal Vein Occlusion.

Authors:  Da-Hu Wang; Cao Gu; Yuan-Zhi Yuan
Journal:  Front Med (Lausanne)       Date:  2022-06-09

2.  Multimodal treatment of Coats-like exudative vitreoretinopathy in Goldmann-Favre syndrome.

Authors:  Fabiola Ramos Nieves; Victor M Villegas; Nimesh A Patel; Audina M Berrocal; Timothy G Murray
Journal:  Am J Ophthalmol Case Rep       Date:  2022-01-29

3.  Peripheral Inflammatory Yellow Exudative Retinal Coats-Like Vitreoretinopathy Misdiagnosed as Acute Retinal Necrosis in a Retinitis Pigmentosa Patient after Cataract Surgery.

Authors:  Lara Tran; Ioannis Papasavvas; Johannes Fleischhauer; Carl P Herbort
Journal:  Case Rep Ophthalmol       Date:  2021-06-18
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.